Journals / Turkish Journal of Gastroenterology / 2017 / Cilt: 28 - Sayı: 1

Gastroesophageal reflux disease and the relationship with Helicobacter pylori

Pages
61–67
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Longterm use of proton pump inhibitor (PPI) may have an impact on the development of atrophy and/or intestinal metaplasia in H. pylori positive patients; therefore, H. pylori eradication is recommended in patients that should use long-term PPI.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:After Helicobacter pylori was identified, and its relationship with peptic ulcer disease was exactly shown, the relationship of this bacterium with gastroesophageal reflux disease (GERD) gained momentum and discussions continue to this day.
📊
Key Findings & Data:We reviewed the literature for the relationship between H. pylori and GERD.
💡
Conclusion & Impact:Longterm use of proton pump inhibitor (PPI) may have an impact on the development of atrophy and/or intestinal metaplasia in H. pylori positive patients; therefore, H. pylori eradication is recommended in patients that should use long-term PPI.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

After Helicobacter pylori was identified, and its relationship with peptic ulcer disease was exactly shown, the relationship of this bacterium with gastroesophageal reflux disease (GERD) gained momentum and discussions continue to this day. We reviewed the literature for the relationship between H. pylori and GERD. According to the existing data, there is no relationship between GERD and H. pylori presence. Successful eradication therapy does not have an impact on the emergence or exacerbation of GERD. However Barrett's esophagus and esophageal adenocarcinoma are less frequent, especially in the presence of CagA positive H. pylori infections. Longterm use of proton pump inhibitor (PPI) may have an impact on the development of atrophy and/or intestinal metaplasia in H. pylori positive patients; therefore, H. pylori eradication is recommended in patients that should use long-term PPI. As a conclusion, H. pylori screening and the eradication decision should be independent of GERD, except for patients that will use long-term PPI

🔖

Cite This Article

MUNGAN, Z., ŞİMŞEK, B. P. (2017). Gastroesophageal reflux disease and the relationship with Helicobacter pylori. Turkish Journal of Gastroenterology, Cilt: 28 - Sayı: 1, 61–67. https://ajindex.com/articles/410733

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Raghunath A, Hungin AP, Wooff D, Childs S. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review. BMJ 2003; 5; 326: 737
  2. Hallerbäck B, Unge P, Carling L, et al. Omeprazole or ranitidine in longterm treatment of reflux esophagitis. The Scandinavian Clinics for United Research Group. Gastroenterology 1994; 107: 1305-11. [CrossRef] 3. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, Eskes SA, Meuwissen SG. Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease. Am J Gastroenterol 1999; 94: 884-7. [CrossRef] 4. Labenz J, Blum AL, Bayerdörffer E, Meining A, Stolte M, Börsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997; 112: 1442-7. [CrossRef] 5. O'Connor HJ, McGee C, Ghabash NM, Cunnane K. Prevalence of gastro-oesophageal reflux disease (GORD) in H.pylori positive peptic ulcer disease and the impact of eradication therapy. Hepatogastroenterology 2001; 48: 1064-8
  3. Cremonini F, Di Caro S, Delgado-Aros S, et al. Meta-analysis: the relationship between Helicobacter pylori infection and gastrooesophageal reflux disease. Aliment Pharmacol Ther 2003; 18: 279-89. [CrossRef] 7. Yaghoobi M, Farrokhyar F, Yuan Y, Hunt RH. Is there an increased risk of GERD after Helicobacter pylori eradication?: a meta-analysis. Am J Gastroenterol 2010; 105: 1007-13.[CrossRef] 8. Qian B, Ma S, Shang L, Qian J, Zhang G. Effects of Helicobacter pylori eradication on gastroesophageal reflux disease. Helicobacter 2011; 16: 255-65. [CrossRef] 9. Saad AM, Choudhary A, Bechtold ML. Effect of Helicobacter pylori treatment on gastroesophageal reflux disease (GERD): meta-analysis of randomized controlled trials. Scand J Gastroenterol 2012; 47: 129-35. [CrossRef] 10. Eissele R, Brunner G, Simon B, Solcia E, Arnold R. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology 1997; 112: 707-17. [CrossRef] 11. Kuipers EJ, Uyterlinde AM, Pe-a AS, et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet 1995; 345: 1525-8. [CrossRef] 12. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 1018-22. [CrossRef] 13. Lundell L, Miettinen P, Myrvold HE, et al. Lack of effect of acid suppression ther